NRIX250117P7500
- 0.00
- 0.000.00%
Nurix Therapeutics Newsroom
We Think Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Drive Business Growth
Barclays Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Maintains Target Price $31
Truist Financial Maintains Nurix Therapeutics(NRIX.US) With Buy Rating
Truist Financial Reaffirms Their Buy Rating on Nurix Therapeutics (NRIX)
Nurix Therapeutics Sees Cash Runway Into 1H27
Nurix Therapeutics Outlines 2025 Goals and Objectives for Advancement of Its Robust Pipeline in Cancer and Autoimmune Diseases
Nurix Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Insider Sale: Chief Legal Officer of $NRIX (NRIX) Sells 5,760 Shares
Express News | Nurix Therapeutics : Anticipate Sharing Additional Clinical Data About Ongoing Phase 1B Expansion Cohort in 2025
Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom's Macroglobulinemia
Express News | Nurix Therapeutics Receives U.S. FDA Fast Track Designation for Nx-5948 for the Treatment of Relapsed or Refractory Waldenstrom’s Macroglobulinemia
Is Nurix Therapeutics (NRIX) the Worst ARK Stock to Buy According to Short Sellers?
A Quick Look at Today's Ratings for Nurix Therapeutics(NRIX.US), With a Forecast Between $29 to $35
Nurix Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Express News | Nurix Therapeutics Inc : H.c. Wainwright Raises Target Price to $35 From $30
Nurix Therapeutics (NRIX) Receives a Buy From Barclays
BTIG Initiates Coverage On Nurix Therapeutics With Buy Rating, Announces Price Target of $35
Oppenheimer Reaffirms Their Buy Rating on Nurix Therapeutics (NRIX)
Nurix Therapeutics (NRIX) Receives a Buy From Stifel Nicolaus
Nurix Therapeutics Reports Promising Trial Results for NX-5948